Morgan Stanley (NYSE:MS) initiated coverage on shares of Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO), a global healthcare company specializing in diabetes care and other serious chronic conditions. The ...

By contrast, Novo Nordisk is both the developer and seller of Wegovy, while Viking Therapeutics's VK2735 has posted impressive results in testing and is now in the later stages of development. Wegovy ...

Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over ...

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid ...

A couple of months ago, healthcare equity research analyst Jared Holz from Mizuho spoke about Viking potentially being an ...

Novo Nordisk, maker of Ozempic and Wegovy ... Why would Trump be OK with forcing Americans to pay more than the rest of the ...

The US Food and Drug Administration (FDA) has approved Novo ... other than diabetes and weight reduction, such as Alzheimer's disease and non-alcoholic steatohepatitis (NASH). Novo Nordisk ...

Novo Nordisk ended the phase three trial in October, a year earlier than expected, in response to positive results. At the time, the Danish company's announcement caused shares of kidney dialysis ...

The Danish drug giant Novo Nordisk, known for its antidiabetes and weight loss drugs ... It is the third time in less than a year that the PMCPA, the self-regulatory body that administers the code of ...

Stocks to Buy or Sell. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other stocks to buy and sell highlighted in Jim Cramer’s latest calls. Jim ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE ... more specifically small-than-expected tariffs that could grow bigger if countries don’t play ball.